ACADIA PHARMACEUTICALS (ACAD) Company Report

Acadia Pharmaceuticals reported adjusted total revenues of $298 million for Q4 2025 and $1.08 billion for the full year 2025, marking the first time annual revenues exceeded $1 billion.
NUPLAZID adjusted net sales were $189 million in Q4 2025 and $692 million for the full year, with 2026 guidance projected between $760 million and $790 million.
DAYBUE net sales reached $110 million in Q4 2025 and $391 million for the full year, with 2026 guidance between $460 million and $490 million, driven by the launch of DAYBUE STIX.
The company provided total revenue guidance for 2026 in the range of $1.22 billion to $1.28 billion and anticipates a Phase II readout for remlifanserin between August and October 2026.

2 days ago

Transcript

ACADIA Reports Strong Q4 and FY 2025 Financial Results, Provides 2026 Guidance, and Updates on Pipeline and EMA Review

ACAD

Earnings

Guidance Update

New Projects/Investments

ACADIA reported Q4 2025 total revenue of $284.0 million, a 9% year-over-year increase, and diluted EPS of $1.60, an 86% increase. Full-year 2025 total revenue reached $1,071.5 million.
The company provided FY 2026 total revenue guidance between $1.22 billion and $1.28 billion, with NUPLAZID net sales projected at $760 million to $790 million and DAYBUE net sales at $460 million to $490 million.
Positive Phase 2 results were reported for Remlifanserin in schizophrenia and Phase 1b results for ACP-204 in cognitive impairment associated with schizophrenia (CIAS). Top-line results for the Phase 2 study of ACP-204 in Alzheimer's Disease Psychosis are anticipated in August-October 2026.
A final EMA CHMP opinion on trofinetide (DAYBUE) is expected this week, and ACADIA plans to pursue a re-examination process, with the next CHMP opinion anticipated around the end of Q2.

2 days ago

Presentation

ACADIA Pharmaceuticals Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Addresses EU Regulatory Setback

ACAD

Earnings

Guidance Update

Accounting Changes

ACADIA Pharmaceuticals achieved adjusted total revenues of $298 million in Q4 2025, a 16% increase from the prior year, and $1.08 billion for the full year 2025, marking the first time annual revenues exceeded $1 billion.
Adjusted NUPLAZID net sales were $189 million in Q4 2025 and $692 million for the full year, representing 17% and 15% year-over-year growth, respectively. DAYBUE net product sales reached $110 million in Q4 2025 and $391 million for the full year, with 13% and 12% year-over-year growth, respectively.
The company provided 2026 financial guidance, projecting total revenues between $1.22 billion and $1.28 billion. This guidance includes NUPLAZID net sales of $760 million to $790 million and DAYBUE global net sales of $460 million to $490 million, with the latter not assuming EU commercial sales due to regulatory status.
ACADIA received a negative trend vote from the CHMP for its trofinetide (DAYBUE) marketing application in the EU but intends to request a reexamination. The company also launched DAYBUE STIX, a new powder formulation, which is expected to contribute to future growth.
A non-recurring $20 million reduction in NUPLAZID net sales was recorded due to a change in estimate for Inflation Reduction Act rebate accruals, related to higher-than-anticipated Medicare volume.

2 days ago

Transcript

ACADIA Pharmaceuticals Reports Strong 2025 Results and Provides 2026 Guidance

ACAD

Earnings

Guidance Update

Product Launch

Acadia reported adjusted total revenues of $298 million for Q4 2025 and $1.08 billion for the full year 2025, marking the first time annual revenues exceeded $1 billion.
The company issued 2026 guidance, expecting total revenues between $1.22 billion and $1.28 billion, with NUPLAZID net sales projected at $760 million to $790 million and DAYBUE net sales at $460 million to $490 million.
DAYBUE STIX, a new powder formulation, received FDA approval in December and is set for a broader commercial launch in early Q2 2026, with potential to unlock over 400 incremental patients.
The EU marketing application for trofinetide (DAYBUE) received a negative trend vote from the CHMP, leading to a planned reexamination, and the 2026 guidance does not include potential EU commercial sales.
A key pipeline catalyst is the Phase 2 readout for remlifanserin in Alzheimer's disease psychosis, anticipated between August and October 2026, which has a potential peak sales of $4 billion across its indications.

2 days ago

Transcript

Acadia Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and Issues 2026 Guidance

ACAD

Earnings

Guidance Update

Product Launch

Acadia Pharmaceuticals reported GAAP total revenues of $284 million for Q4 2025 and $1.07 billion for the full year 2025, marking the first time the company surpassed $1 billion in annual revenue.
NUPLAZID GAAP net sales were $174 million in Q4 2025, impacted by a $20 million non-recurring IRA rebate accrual charge, while DAYBUE net sales reached $110 million.
The company posted net income of $274 million, or $1.60 per diluted share, for Q4 2025, including a $250 million non-cash income tax benefit. Cash, cash equivalents, and investment securities stood at $820 million as of December 31, 2025.
Full year 2026 guidance projects total revenues between $1.22 billion and $1.28 billion, with NUPLAZID net sales of $760 million to $790 million and DAYBUE net sales of $460 million to $490 million.
The DAYBUE STIX powder formulation is preparing for a broader launch in early Q2 2026, and remlifanserin Phase 2 study top-line results are anticipated between August and October 2026.

2 days ago

8-K

Acadia Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance

ACAD

Earnings

Guidance Update

Product Launch

Acadia Pharmaceuticals reported GAAP total revenues of $284 million for the fourth quarter of 2025 and $1.07 billion for the full year 2025, marking the first time the company surpassed $1 billion in annual revenue.
For the full year 2026, the company provided GAAP total revenue guidance in the range of $1.22 to $1.28 billion, with NUPLAZID net sales projected at $760 to $790 million and DAYBUE net sales at $460 to $490 million.
NUPLAZID GAAP net sales were $174 million and DAYBUE GAAP net sales were $110 million for the fourth quarter of 2025.
The company ended 2025 with $820 million in cash, cash equivalents, and investment securities.
Key upcoming operational highlights include the planned broader launch of DAYBUE STIX in early Q2 2026 and top-line results from the remlifanserin Phase 2 study expected between August and October 2026.

2 days ago

Press Release

Acadia Pharmaceuticals Provides Update on EU Regulatory Submission for Trofinetide

ACAD

Acadia Pharmaceuticals received a negative trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorization Application (MAA) for trofinetide for Rett syndrome in the European Union.
The company anticipates a negative opinion but plans to request a re-examination by the CHMP upon formal adoption of the opinion.
Despite the EU setback, trofinetide has been approved in the United States, Canada, and Israel, with over 1,000 patients globally currently on active treatment.

Feb 2, 2026, 9:05 PM

Press Release

ACADIA Pharmaceuticals Provides 2028 Sales Outlook and Pipeline Updates

ACAD

Guidance Update

Product Launch

New Projects/Investments

ACADIA Pharmaceuticals projects its commercial brands, NUPLAZID and DAYBUE, to achieve over $1 billion in sales in 2025 and grow to approximately $1.7 billion in 2028, with $1 billion from NUPLAZID and $700 million from DAYBUE.
The company's pipeline includes four molecules targeting larger markets, with a combined peak sales potential of $11 billion, and Remlifanserin alone represents a $4 billion opportunity. Top-line results for Remlifanserin in Alzheimer's disease psychosis are expected between August and October of 2026.
DAYBUE STIX, a new powder-for-oral formulation, was approved on December 12th and will be fully available by Q2 2026. A CHMP opinion for trofinetide is anticipated in Q1 2026.
ACADIA plans global expansion for DAYBUE, including anticipated European approval in Q1 2026, and is increasing its NUPLAZID commercial field force by 30% starting in Q1 2026.
The company is actively pursuing business development for late-stage neurological and rare disease opportunities, with an ambition to expand into other rare disease areas like cardiac, endocrine, and metabolic.

Jan 13, 2026, 5:45 PM

Transcript

ACADIA Pharmaceuticals Outlines 2028 Sales Targets and Pipeline Milestones at J.P. Morgan Healthcare Conference

ACAD

Guidance Update

Product Launch

New Projects/Investments

ACADIA Pharmaceuticals projects combined net sales for its commercial brands, NUPLAZID and DAYBUE, to reach $1.7 billion in 2028, up from over $1 billion in 2025, with NUPLAZID contributing $1 billion and DAYBUE $700 million.
The company's development pipeline includes four molecules with a potential combined peak sales opportunity of $11 billion, notably Remlifansirin with a $4 billion potential across its indications.
Key upcoming milestones in 2026 include the expected CHMP opinion for Trofinetide in Q1, the start of the first-in-human study for ACP-271 in Q1, and top-line results for Remlifansirin in Alzheimer's disease psychosis between August and October.
Commercial growth strategies include increasing the NUPLAZID field force by 30% in Q1 2026 and the recent approval and rollout of DAYBUE Sticks (a new powder-for-oral formulation) to drive further DAYBUE sales.
ACADIA is actively pursuing business development for late-stage therapeutics to expand its rare disease portfolio beyond neurology, supported by a strong balance sheet.

Jan 13, 2026, 5:45 PM

Transcript

ACADIA Pharmaceuticals projects $1.7 billion in 2028 commercial sales and highlights pipeline potential

ACAD

Guidance Update

Product Launch

New Projects/Investments

ACADIA Pharmaceuticals projects its commercial brands, NUPLAZID and DAYBUE, to reach approximately $1.7 billion in combined sales by 2028, comprising $1 billion from NUPLAZID and $700 million from DAYBUE.
The company expects top-line results for its Remlifansirin program in Alzheimer's disease psychosis between August and October 2026 , with the overall pipeline holding a potential peak sales opportunity of $11 billion combined, including $4 billion for Remlifansirin.
ACADIA launched DAYBUE Sticks, a new powder-for-oral formulation, with limited rollout in Q1 2026 and full availability by Q2 2026 , and anticipates a CHMP opinion for Trofinetide (DAYBUE) in Q1 2026 for European market expansion.
Operating expenses are projected to increase in 2026 due to the 30% expansion of the NUPLAZID commercial field force and continued pipeline investments , alongside an active pursuit of business development for late-stage assets.

Jan 13, 2026, 5:45 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for ACADIA PHARMACEUTICALS.

Q4 2025

Feb 25, 2026

→

Q3 2025

Nov 5, 2025

→

Q2 2025

Aug 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Catherine Owen Adams say about margins?What are ACADIA PHARMACEUTICALS's strategic priorities?How is ACADIA PHARMACEUTICALS positioned vs competitors?How did ACADIA PHARMACEUTICALS do last quarter?

ACADIA PHARMACEUTICALS (ACAD)

Analyst Earnings Quarterly Reports

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Executives

Catherine Owen Adams

Elizabeth H.Z. Thompson

Jennifer J. Rhodes

Mark C. Schneyer

Scott Cenci

Thomas Garner

Board Members

Adora Ndu

Edmund P. Harrigan

Elizabeth A. Garofalo

James M. Daly

Julian C. Baker

Laura A. Brege

Stephen R. Biggar

Analyst Coverage

Sumant Kulkarni

Tessa Romero

Marc Goodman

Ritu Baral

David Hoang

Jason Butler

Tazeen Ahmad

Ami Fadia

Charles Duncan

Joel Beatty

Julian Pino

Sean Laaman

Ash Verma

Ashwani Verma

Caroline Palavicino-Maggio

Gregory Renza

Jack Allen

Malcolm Hoffman

Nevin Varghese

Paul Matteis

Rudy Li

Yatin Suneja

Basma Radwan Ibrahim

Brian Abrahams

Chi Wen Chin

Danielle Brill

Greg Rirenza

Jay Olson

Jeff Hung

Julian Hung

Keith Tapper

Mark Breidenbach

Mark Hoffman

Michael Riad

Salveen Richter

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent